Recardio

Regenerative Cardiac

  • About Us
    • Profile
    • Management
    • Boards
    • Awards
  • Science
    • Background
    • Rationale
    • Therapy
  • Clinical
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News Center

Oct 17 2017

Recardio presented at BIO Investor Forum 2017 in San Francisco

San Francisco, Oct. 17, 2017 – Recardio presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2017 in San Francisco.

Read More

Written by Recardio · Categorized: Uncategorized

Oct 12 2017

Recardio completes Phase 1 Study

San Francisco, October 12th, 2017 – Recardio Inc. successfully completes Phase 1 study for Dutogliptin.

Read More

Written by Recardio · Categorized: Uncategorized

Aug 28 2017

Umbrella Patent for the treatment of cardiovascular diseases in the EU

San Francisco, Aug. 28th, 2017 – RECARDIO, announced that the European Patent Office (EPA) has issued the notice of allowance for its innovative use patent for the treatment of ischemic diseases.

Read More

Written by Recardio · Categorized: Uncategorized

Jul 25 2017

Recardio at ESC 2017 – The European Society of Cardiology Congress

San Francisco, Jul. 25, 2017 – Recardio is participating in the European Society of Cardiology Congress in Barcelona.

Read More

Written by Recardio · Categorized: Uncategorized

Jun 21 2017

Recardio appoints Scientific Advisory Board

San Francisco, June 21st, 2017 – Recardio Inc. today announced that it has appointed its newly formed Scientific Advisory Board, reflecting the company’s entering the clinical phase 2 development in 2017.

Read More

Written by Recardio · Categorized: Uncategorized

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »
  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2021 · All Rights Reserved

Copyright © 2021 · Recardio on Genesis Framework · WordPress · Log in